Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America · 9 authors, 15 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This paper describes the statistical methods for the VIDA study, a 36-month prospective matched case-control study with a nested cohort, which aimed to estimate the pathogen-specific burden and adverse consequences of moderate-to-severe diarrhea in African children after rotavirus vaccine introduction.
The VIDA study is a 36-month prospective, matched case-control study designed to estimate the etiology, incidence, and adverse clinical consequences of moderate-to-severe diarrhea (MSD) in children aged 0–59 months in sub-Saharan Africa, conducted after rotavirus vaccine introduction. The study enrolled MSD cases and matched controls from sentinel health centers at 3 sites, collecting clinical, epidemiological, and anthropometric data at enrollment and a follow-up visit approximately 60 days later. Stool samples were analyzed for enteric pathogens using both conventional methods and quantitative PCR. Key statistical methods include estimating pathogen-specific attributable fractions (AF) and attributable incidences (AI) for MSD, with bootstrap methods for confidence intervals. A nested prospective cohort study within the case-control design allowed assessment of the association between MSD and outcomes like vital status and linear growth. The methods aim to produce robust estimates of disease burden to inform interventions.
